Final Adjusted Model*† for the Likelihood of Guideline Consistent Antiviral Prescription
| Sign/Symptom | Estimate (β coefficient) | aOR (95% CI) |
|---|---|---|
| PCR guided care | 0.53 | 1.71 (1.18–2.46) |
| Duration of symptoms (≤2 days vs >2 days) | 1.76 | 5.82 (4.14–8.19) |
| Myalgia | 1.29 | 3.62 (2.32–5.63) |
| Fever | 0.88 | 2.41 (1.50–3.89) |
| Enlarged tonsils | −1.04 | 0.35 (0.20–0.64) |
| Clinic 2 | 0.12 | 1.13 (0.75–1.71) |
| Clinic 3 | 0.77 | 2.15 (1.39–3.35) |
| Unclear lungs | 0.82 | 2.28 (1.27–4.08) |
| Nasal discharge | 0.79 | 2.20 (1.18–4.10) |
| Chills | 0.80 | 2.20 (1.17–4.24) |
| Intercept | −5.10 | —————- |
↵* Hosmer-Lemeshow χ2 statistic, 5.67; P = .68; AUROCC, 0.86.
aOR, adjusted odds ratio; CI, confidential interval; PCR, polymerase chain reaction.